Bechtle

Initial buy, P/E ratio of 15 is favorable compared to the historical average.

Of course, a lot depends on the economic environment in DE/FR, which will improve again in the long term.

Have a nice weekend!

Depot review November 2024 - The depot is growing despite larger withdrawals 🚀

Before I continue with the second part of my investment story, I would first like to share my portfolio review for November.

The second half of November was almost quiet compared to what happened at the beginning of November. Trump was elected, triggering a veritable run on the stock markets. Germany was finally freed from the traffic lights and there were also some exciting topics in the private sphere. I sold a few shares back in October to generate the equity I needed to start building a house. This continued a little further in November.

Overall, my savings rate will also (have to) be lower over the next few months. Less into the portfolio and more into the "buffer account" for building the house. Nevertheless, around €500 per month will continue to be invested and this will be pushed up again as quickly as possible.

After selling 6 shares and an ETF in October, I sold parts of my MSCI World ETF for around €13,000.

But now it's finally time to look at the hard figures:

Monthly view:

In total, November was +6,3%. This corresponds to price gains of ~20.000€.

The MSCI World (benchmark) was +7.3% and the S&P500 +5.1%

Winners & losers:

A look at the winners and losers is particularly exciting this month:

On the winning side with a total of almost €5,000 in price gains, my crypto investments in Bitcoin and Ethereum. This is followed by the long runner NVIDIA with price gains of just under €2,000. 4th and 5th place then goes to the cybersecurity sector with Palo Alto Networks and Crowdstrike.

On the loser side looks very quiet this month. Amgen is still the worst performer with losses of ~€600 due to a weight loss drug that failed to fully meet Wall Street's hopes. This is followed by Sartorius with share price losses of €200. Places 3-5 are then occupied by share price losses of less than €100. All in all, a month with almost no losers.

The performance-neutral movements in October amounted to just under € -6,000. Parts have already been removed here for private topics.

current year:

My performance in the current year is +29,9% and thus above my benchmark, the MSCI World with 26.9%.

In total, my portfolio currently stands at ~345.000€. This corresponds to an absolute growth of ~€93,000 in the current year 2023. ~72.000€ of this comes from price gains, ~3.300€ from dividends / interest and ~16.000€ from additional investments.

Dividend:

• Dividends in November were 21% above the previous year at ~€160
• Procter & Gamble is in the lead with a (gross) dividend of €50 every 3 months.
• In the current year, the dividends after 11 months are +25% over the first 11 months of 2023 at ~2.500€

Buying & selling:

• I bought in November for significantly reduced ~700€
• As always, my savings plans were executed:
• Blue ChipsProcter & Gamble $PG (-1.24%) TSMC $TSM (+0.43%) S&P Global $SPGI (+0.02%) Alphabet $GOOGL (+0.94%) Johnson & Johnson $JNJ (+0.03%) Amgen $AMGN (+0.51%) Herhey $HSY (+0.03%) Alimentation Couche-Tard $ATD (+1.09%) Caterpillar $CAT (+0.86%)
• 
  GrowthBechtle $BC8 (+0.82%)
• 
  ETFsMSCI World $XDWD (+0.24%) Nikkei 225 $XDJP (-0.32%) and the WisdomTree Global Quality Dividend Growth $GGRP (-0.09%)
• 
  CryptoBitcoin $BTC (-1.81%) and Ethereum $ETH (-0.29%)
• 
  Sales as mentioned at the beginning, there was a larger part of my MSCI World holdings in November

Target 2024 & outlook 2025:

My goal for this year is to reach €300,000 in my portfolio. Due to the extremely positive market performance in the current year, my portfolio already stands at ~€345,000 at the end of November.

As is well known, one should not praise the day before the evening, but I am optimistic that my portfolio will not fall so far in December that I will not reach my target.

What will happen in 2025? The logical goal would of course be to reach €400,000. However, due to the upcoming house construction, part of the assets will be invested in the house construction. If I include the property in my statement of assets, the target of €400,000 would of course not change. However, as I am tracking my liquid assets here, I will probably refrain from doing so.

Therefore, my year-end target for 2025 will probably be closer to the final balance for 2024. So around €350,000 at the end of 2025.

How are things looking for you? Have you already thought about your plans for 2025?

#dividends

#dividende

#rückblick

#depotupdate

#aktie

#stocks

#etfs

#crypto

#personalstrategy

Analyst updates, 19.11.

⬆️⬆️⬆️

- JEFFERIES raises the price target for NETFLIX from USD 800 to USD 1000. Buy. $NFLX (+0.09%)

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS from EUR 200 to EUR 210. Buy. $SIE (-0.29%)

- DZ BANK raises the price target for WALT DISNEY from USD 115 to USD 130. Buy. $DIS (-0.24%)

- KEPLER CHEUVREUX raises the target price for ALZCHEM from EUR 69 to EUR 73. Buy. $ACT (-1.9%)

⬇️⬇️⬇️

- BOFA downgrades SIEMENS from Buy to Neutral and raises target price from EUR 196 to EUR 200. $SIE (-0.29%)

- BERENBERG lowers the price target for BAYER from EUR 28 to EUR 22. Hold. $BAYN (+0.17%)

- BERENBERG lowers the price target for SMA SOLAR from EUR 21 to EUR 14. Hold. $S92 (+0.6%)

- DZ BANK downgrades SHOPIFY from Hold to Sell and raises target price from USD 68 to USD 91. $SHOP (+0.9%)

- STIFEL lowers the price target for BECHTLE from EUR 50 to EUR 45. Buy. $BC8 (+0.82%)

- WARBURG RESEARCH lowers the price target for JUNGHEINRICH from EUR 49 to EUR 47. Buy. $JUN3 (-0.4%)

- HAUCK AUFHÄUSER IB lowers the target price for KNAUS TABBERT from EUR 16 to EUR 8. Sell. $KTA (+0.16%)

- DEUTSCHE BANK RESEARCH lowers the price target for JOST WERKE from EUR 70 to EUR 60. Buy. $JST (+1.33%)

- GOLDMAN lowers the price target for TEAMVIEWER from EUR 18 to EUR 17. Buy. $TMV (-2.93%)

Analyst updates, 18.11.

⬆️⬆️⬆️

- MORGAN STANLEY raises the price target for SIEMENS from EUR 212 to EUR 220. Overweight. $SIE (-0.29%)

- HSBC raises the target price for RHEINMETALL from EUR 660 to EUR 700. Buy. $RHM (-0.78%)

- HSBC raises the target price for DEUTSCHE TELEKOM from EUR 33.50 to EUR 34. Buy. $DTE (-0.92%)

- DEUTSCHE BANK RESEARCH raises the price target for ALLIANZ SE from EUR 275 to EUR 310. Buy. $ALV (-0.66%)

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS ENERGY from EUR 52 to EUR 57. Buy. $ENR (+2.08%)

- UBS upgrades AIR PRODUCTS & CHEMICALS from Neutral to Buy and raises target price from USD 338 to USD 375. $APD (+0.04%)

- ODDO BHF raises the price target for SWISS RE from CHF 127 to CHF 138. Outperform. $SREN (+0.04%)

- BARCLAYS raises the price target for MUNICH RE from EUR 523 to EUR 551. Overweight. $MUV2 (-1.1%)

- BARCLAYS raises the target price for HANNOVER RÜCK from EUR 206 to EUR 217. Underweight. $HNR1 (-0.97%)

⬇️⬇️⬇️

- MORGAN STANLEY lowers the target price for BAYER from EUR 35 to EUR 30. Equal-Weight. $BAYN (+0.17%)

- KEPLER CHEUVREUX lowers the target price for SIEMENS HEALTHINEERS from EUR 60.50 to EUR 59. Buy. $SHL (-1.01%)

- KEPLER CHEUVREUX downgrades KNAUS TABBERT to Hold. Target price EUR 15. $KTA (+0.16%)

- DEUTSCHE BANK RESEARCH lowers the price target for SGL CARBON from EUR 10.60 to EUR 9. Buy. $SGL (-1.08%)

- DEUTSCHE BANK RESEARCH lowers the price target for PVA TEPLA from EUR 18 to EUR 14.50. Hold. $TPE (+1.5%)

- DEUTSCHE BANK RESEARCH lowers the price target for KERING from EUR 340 to EUR 320. Buy. $KER (+0.06%)

- ODDO BHF downgrades BECHTLE to Neutral. Target price 37 EUR. $BC8 (+0.82%)

- BARCLAYS lowers the price target for UNITED INTERNET from EUR 27 to EUR 23. Equal-Weight. $UTDI (-1.53%)

- BARCLAYS lowers the price target for 1&1 from EUR 19 to EUR 17. Equal-Weight. $1U1 (-0.61%)

- BERENBERG lowers the target price for AIR LIQUIDE from EUR 195 to EUR 190. Buy. $AI (-0.22%)

- HSBC downgrades PORSCHE SE from Hold to Reduce and lowers target price from EUR 36 to EUR 26. $PAH3 (+0.42%)

⬆️⬆️⬆️

- UBS raises its price target for NVIDIA from USD 150 to USD 185. Buy. $NVDA (+2.01%)

- METZLER raises the price target for MUNICH RE from EUR 535 to EUR 543. Buy. $MUV2 (-1.1%)

- GOLDMAN lowers the target price for NOVO NORDISK from DKK 1040 to DKK 1025. Buy. $NOVO B (-17.74%)

- GOLDMAN upgrades MTU from Neutral to Buy and raises target price from EUR 276 to EUR 400. $MTX (-0.47%)

- GOLDMAN upgrades BASF from Neutral to Buy and raises target price from EUR 45 to EUR 53. $BAS (-0.12%)

- DEUTSCHE BANK RESEARCH raises the price target for FRESENIUS SE from EUR 42 to EUR 44. Buy. $FRE (-0.84%)

- DEUTSCHE BANK RESEARCH raises the price target for EMBRACER from SEK 24 to SEK 28. Hold. $TH9A

- DEUTSCHE BANK RESEARCH raises the price target for AMADEUS IT from EUR 62 to EUR 65. Hold. $AMS (+1.89%)

- DEUTSCHE BANK RESEARCH raises the price target for NEMETSCHEK from EUR 85 to EUR 100. Hold. $NEM (+1.42%)

- WARBURG RESEARCH raises the price target for DÜRR from EUR 32 to EUR 33. Buy. $DURYY

- HAUCK AUFHÄUSER IB upgrades CANCOM from Hold to Buy. Target price EUR 32. $COK (+0.99%)

- ODDO BHF upgrades GENERALI to Neutral. Target price EUR 26.10. $G (-0.26%)

- METZLER raises the price target for HEIDELBERG MATERIALS from EUR 131 to EUR 138. Buy. $HEI (-0.69%)

- BERENBERG raises the price target for FLATEXDEGIRO from EUR 16 to EUR 18. Buy. $FTK (-0.34%)

- BERENBERG raises the price target for FREENET from EUR 29 to EUR 32. Buy. $FNTN (-1.23%)

- JPMORGAN raises the target price for HEIDELBERG MATERIALS from EUR 108 to EUR 149. Overweight. $HEI (-0.69%)

⬇️⬇️⬇️

- UBS lowers the price target for MUNICH RE from EUR 560 to EUR 540. Buy. $MUV2 (-1.1%)

- ODDO BHF downgrades MODERNA to Outperform. Target price USD 86. $MRNA (-1.12%)

- UBS downgrades VALE from Buy to Neutral and lowers target price from USD 14 to USD 11.50. $VALE (+0.47%)

- DZ BANK lowers target price for DEUTZ from EUR 6.80 to EUR 5.80. Buy. $DEZ (-1.18%)

- DZ BANK lowers the price target for BECHTLE from EUR 51 to EUR 45. Buy. $BC8 (+0.82%)

- BERENBERG lowers the target price for ESTEE LAUDER from USD 87 to USD 76. Hold. $EL (-0.42%)

- RBC lowers the target price for ASOS from GBP 4.60 to GBP 4. Sector Perform. $ASC (-0.95%)

- RBC lowers the price target for EVOTEC from EUR 12 to EUR 11.60. Outperform. $EVT (+1.24%)

- RBC lowers the price target for VESTAS from DKK 222 to DKK 156. Outperform. $VWS (-2.71%)

- BERENBERG lowers the price target for SUSS MICROTEC from EUR 80 to EUR 75. Buy. $SMHN (+0.76%)

- JEFFERIES downgrades NEL from Hold to Underperform and lowers target price from NOK 5.50 to NOK 3. $NEL (-0.43%)

- RBC lowers the price target for BMW from EUR 81 to EUR 80. Sector Perform. $BMW (+0.87%)

- JEFFERIES lowers the price target for KNAUS TABBERT from EUR 26 to EUR 20. Hold. $KTA (+0.16%)

08.11.2024

US Federal Reserve lowers key interest rate by 25 basis points
+ Goldman raises Biontech to 'Buy' - target up to 137 dollars + Bechtle higher - remains optimistic for the final quarter + Redcare at three-year high

The US Federal Reserve has lowered its key interest rate by 25 basis points. This decision had been firmly expected on the markets. The decision was taken unanimously by the Federal Open Market Committee (FOMC). The decision, which was taken in the week of Donald Trump's re-election as US president, followed an initial cut of 50 basis points in September and will bring the key interest rate to a range of 4.50 to 4.75 percent. US Federal Reserve officials have said that these rate cuts are justified because they are more confident that inflation will return to the central bank's target and because they believe that interest rates are still high enough to dampen economic activity even after the recent cuts. "The Council judges that the risks to achieving the employment and inflation objectives are roughly balanced," the Fed's statement said. Trump's election victory has the potential to reshape the economic outlook as the Republicans' likely majority in Congress allows for a sweeping change of course on taxes, spending, immigration and trade. The changing outlook has in turn raised questions on Wall Street as to whether the Fed will change its previous expectation that interest rates could be steadily lowered over the next year or two.

The US investment bank Goldman Sachs has Biontech $BNTX (+0.93%) from "Neutral" to "Buy" and raised its price target from 90 to 137 US dollars. Analyst Chris Shibutani now includes BNT327 - an antibody that the Mainz-based company is testing against various solid tumors - in his buy recommendation published on Friday. The investment story is moving further away from the difficult-to-assess Covid vaccine market.

With Bechtle $BC8 (+0.82%) a very weak 2024 share was in demand in pre-market trading on Friday. Following the IT service provider's final quarterly figures, the shares rose by 2.7 percent in Tradegate trading compared to the Xetra closing price. An attempt to recover from the low since 2020 thus continues. So far this year, the share has lost around 28% despite the recent stabilization and a gain of 3.3% the day before. Since the record high in 2021, the share price has even more than halved. According to a trader, the business environment for Bechtle in the third quarter was characterized by challenges. The results showed a mixed picture with weak demand in the core markets of Germany and France, but solid organic growth in other international markets, and another trader emphasized that Bechtle is optimistic about the future and continues to expect an improvement in the fourth quarter. However, the first mentioned trader sees risks in the fact that public IT spending in Germany could suffer for the time being from the end of the traffic light coalition.

The good performance of the shares of Redcare Pharmacy $RDC (+1.71%) continued on Friday with a high since December 2021. The shares were already the biggest MDax gainer in 2023 and are among the better performers in the mid-cap index this year. On Friday, they rose by up to three percent to EUR 157.60 in early Xetra trading. So far this year, they have repeatedly struggled in the EUR 153 to 154 range.

Friday: Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Apple USD 0.25

Pfizer USD 0.42

ConocoPhillips USD 0.78

Wells Fargo USD 0.4

Quarterly figures / company dates USA / Asia

07:00 Sony quarterly figures

Untimed: Baxter International quarterly figures

Quarterly figures / Company dates Europe

07:00 LEG Immobilien | Richemont Quarterly figures

07:30 Bechtle | Deutsche Wohnen Quarterly figures

08:00 Banca Monte dei Paschi | International Consolidated Airlines Quarterly figures

10:00 Freenet earnings call and strategy update until 2028

10:30 Bechtle analyst and press conference

14:00 Pernod Ricard AGM

Economic data

• 06:00 JP: Leading indicators 9/24 (preliminary)
• 08:00 DE: Domestic tourism | Truck toll mileage index October
• 09:00 DE: Bundestag, Plenum, Berlin
• 11:30 DE: Government Pk, Berlin
• 16:00 US: Consumer Sentiment Index Uni Michigan (1st survey) November FORECAST: 71.0 previous: 70.5

Slump in share price $BC8 (+0.82%) - Annual forecasts overturned and customers bail out.

Source: https://www.finanzen.net/nachricht/aktien/ziele-kassiert-bechtle-aktie-tiefrot-bechtle-kassiert-jahresprognose-nach-schwachem-dritten-quartal-13936223

How do you actually see the performance of $BC8 (+0.82%) ?

I think Bechtle is pretty weak at the moment or has been recently. 🤷‍♂️

From all-time high to all-time high - time to take a look in my cellar 📉

The stock markets only know one direction at the moment and even September, generally the worst month on the stock markets, is heading for a clear green result.

Of course, this can also be seen in my portfolio in the following picture. What I find much more exciting in such situations, however, is always the view to the very bottom, where it turns red and which is generally not shown here.

Now it turns red and negative:

Even though many things are going well, some things are not going well. For the most part, these are still the former corona winners like Pfizer $PFE (+1.49%) Sea $SE (-1.3%) Block $SQ (+1.31%) or Atlassian $TEAM

However, Pfizer's overall performance is not quite as bad, as there has of course been a lot of dividend growth over the last few years.

Nike $NKE (-6.85%) and Hershey $HSY (+0.03%) are also not doing themselves any favors at the moment, but are still in the savings plan. Just like Bechtle $BC8 (+0.82%)

My China ETF is currently the phoenix from the ashes, I was surprised myself that it has almost reached 0 😂

Towards the end of the year, I will analyze the losers again. Will they get another year of probation? Or will one stock or another be thrown out?

I usually look at this between Christmas and New Year's Eve.

What's your situation? What are your skeletons in the closet doing?

#etfs
#personalstrategy
#stocks

Depot review August 2024 - calm before the (September) storm?

While September has lived up to its name so far (worst month on the stock market, negative in more than 50% of cases), August was a boring month in my portfolio. In keeping with the vacation season, my portfolio also shifted down a gear.

Monthly view:

In total, August was +0,5%. This corresponds to price losses of ~1.400€.

This was therefore unable to fully make up for the losses from the previous month of July (-2.2%).

Winners & losers:

There was therefore not much going on on the winners' and losers' side in August.

On the winning side are MercadoLibre and Palo Alto Networks at the top with ~€1,000 each. They are followed by Starbucks, Crowdstrike and Meta.

On the loser side are the crypto assets in my portfolio in August. Ethereum at the top with price losses of €1,500, Bitcoin in 3rd place with €900. Alphabet with ~€1,000 in price losses.

The performance-neutral movements in August were just under €4,000, after being somewhat lower in the previous months due to private issues.

However, only just under €1,400 of this went into shares, the rest is cash.

Current year:

My performance in the current year is +15,3% and thus still slightly above my benchmark, the MSCI World at 14.2%. Even if the gap is slowly narrowing.

In total, my portfolio currently stands at ~312.000€. This corresponds to an absolute growth of ~€60,000 in the current year 2023. ~44.000€ of this comes from price gains, ~2.400€ from dividends / interest and ~13.000€ from additional investments.

Dividend:

• Dividends in August were 24% above the previous year at ~€160
• Procter & Gamble is in the lead with almost €50 (gross) dividends every 3 months
• In the current year, dividends after 7 months are +24% over the first 8 months of 2023 at ~1.840€

Buys & sells:

• I bought in August for approx. 1.400€
• As always, my savings plans were executed:
• Blue chipsTSMC $TSM (+0.43%) S&P Global $SPGI (+0.02%) Procter & Gamble $PG (-1.24%) Johnson & Johnson $JNJ (+0.03%) Hershey $HSY (+0.03%) Caterpillar $CAT (+0.86%) Amgen $AMGN (+0.51%) Alphabet $GOOG (+1.03%) Alimentation Couche-Tard $ATD (+1.09%)
• 
  GrowthBechtle $BC8 (+0.82%) Synopsys $SNPS (-1.06%)
• 
  ETFsMSCI World $XDWD (+0.24%) Nikkei 225 $XDJP (-0.32%) and the WisdomTree Global Quality Dividend Growth $GGRP (-0.09%)
• 
  CryptoBitcoin $BTC (-1.81%) and Ethereum $ETH (-0.29%)
• 
  Sales there were none in August

Target 2024:

My goal for this year is to reach €300,000 in my portfolio. Due to the extremely positive market performance this year, my portfolio currently stands at ~€312,000.

However, after the first few days of trading in September, my portfolio only stands at €304,000. Compared to the level of €320,000 at the end of June, this is now a significant decline in total assets.

It therefore remains exciting to see how the share price will develop in the last third of the year. However, if we see a year-end rally after a weak September, I am optimistic about my target.

#dividends

#dividende

#rückblick

#depotupdate

#aktie

#stocks

#etfs

#crypto

#personalstrategy